Clinical application of botulinum toxin type A in the treatment of thyroid-associated ophthalmopathy
10.3980/j.issn.1672-5123.2023.7.11
- VernacularTitle:A型肉毒毒素在甲状腺相关眼病治疗中的应用
- Author:
Hao-Hao CUI
1
;
Qing SHAO
1
Author Information
1. Department of Ophthalmology, the First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
- Publication Type:Journal Article
- Keywords:
botulinum toxin type A;
thyroid-associated ophthalmopathy;
strabismus;
upper eyelid retraction;
extraocular muscle
- From:
International Eye Science
2023;23(7):1120-1125
- CountryChina
- Language:Chinese
-
Abstract:
Thyroid-associated ophthalmopathy(TAO)is an autoimmune inflammatory disease involving multiple orbital tissues with a variety of clinical manifestations, which has serious effects on the life quality of patients.Interventions of TAO mainly include medical treatment to stabilize thyroid function, reduce inflammation and regulate immune function, as well as surgical treatment to relieve ocular symptoms. Botulinum toxin type A can paralyze muscles by blocking nerve impulse conduction at the neuromuscular junction, which is of certain therapeutic value for restrictive strabismus due to extraocular muscle involvement and upper eyelid retraction due to involvements of levator palpebrae superioris and Müller's muscle in TAO patients, especially when they have surgical contraindications, lack surgical opportunity, or refuse surgery. This paper reviews the application of botulinum toxin type A in the treatment of TAO, focusing on its pharmacological mechanism, dosage, effectiveness, and possible complications when treating restrictive strabismus and upper eyelid retraction, and discussing potential therapeutic values of botulinum toxin type A for intraocular pressure elevation, glabellar frown lines and dry eye caused by extraocular muscle compression in TAO patients, in order to provide a reference for clinical intervention.
